Compare DERM & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | ORGO |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United States | United States |
| Employees | N/A | 854 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 181.4M |
| IPO Year | 2021 | 2016 |
| Metric | DERM | ORGO |
|---|---|---|
| Price | $6.15 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.67 | $8.50 |
| AVG Volume (30 Days) | 156.5K | ★ 594.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.72 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.20 | ★ 17.04 |
| 52 Week Low | $4.31 | $1.34 |
| 52 Week High | $9.56 | $7.08 |
| Indicator | DERM | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 33.35 |
| Support Level | $5.92 | $1.34 |
| Resistance Level | $6.59 | $2.69 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 0.53 | 17.65 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.